Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 801–900 of 1,006
Gurlo, T., Costes, S., Hoang, J. D., Rivera, J. F., Butler, A. E., & Butler, P. C. (2016) · JCI Insight · doi:10.1172/jci.insight.89590 · Cited by 23
“This may explain why therapeutic efforts to reduce the burden of extracellular amyloid have generally been unsuccessful in modifying the disease course in protein misfolding diseases (43).”
BackgroundFinke, J., & Banks, W. (2017) · Human Antibodies · doi:10.3233/hab-160306 · Cited by 18
Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease
Nakamura, N., Ohyagi, Y., Imamura, T., Yanagihara, Y. T., Iinuma, K., Soejima, N., Murai, H., Yamasaki, R., & Kira, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160344 · Cited by 24
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.016 · Cited by 25
Self-citationRetractedTherapeutic Strategies for Alzheimer’s Disease in the View of Diabetes Mellitus
Ohyagi, Y., Miyoshi, K., & Nakamura, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_11 · Cited by 23
Does Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 25
“Monoclonal antibodies designed to target and remove abnormal amyloid beta have shown no improvement in cognitive function in early and late stage AD patients (Doody et al., 2014; Salloway et al., 2014; Honig et al., 2018).”
BackgroundLebrec, J., Ascher‐Svanum, H., Chen, Y.-F., Reed, C. C., Kahle‐Wrobleski, K., Hake, A. M., Raskin, J., Naderali, E. K., Schuster, D., Heine, R. J., et al. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0264-8 · Cited by 27
Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
Self-citationAdvancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 44
“Though these latter three antiamyloid therapies have been shown to e ff ectively reduce A β , only lecanemab and donanemab were shown to reduce cognitive decline [22 – 24].”
BackgroundNrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease
Soni, P., Sharma, S. M., Pieper, A. A., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00586 · Cited by 25
DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells
Xiang, J., Zhang, W., Cai, X., Cai, M., Yu, Z., Yang, F., Zhu, W., Li, X.-T., Wu, T., Zhang, J., et al. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.02.025 · Cited by 19
“Several clinical trials show that antibodies against Ab bring no benefit to the cognition of AD patients.(4,5) Clinical trials also repeatedly demonstrate that targeting g-secretase with potent inhibitor causes unwanted side effects without cognitive improvement.”
BackgroundOrtega, R. L., Dakterzada, F., Arias, A., Blasco, E., Naudí, A., Purroy, F. F., & Piñol‐Ripoll, G. (2019) · Current Aging Science · doi:10.2174/1874609812666190112095430 · Cited by 23
Links Between Adiponectin and Dementia: From Risk Factors to Pathophysiology
Chen, R., Shu, Y., & Zeng, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00356 · Cited by 26
Robinson, R. A. S., Williams, I. C., Cameron, J. L., Ward, K., Knox, M. L., Terry, M. H., Tamres, L. K., Mbawuike, U., Garrett, M., & Lingler, J. H. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12076 · Cited by 23
Li, Y., Dai, S., Huang, N., Wu, J., Yu, C., & Luo, Y. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2114 · Cited by 26
Molecular subtyping of Alzheimer’s disease with consensus non-negative matrix factorization
Zheng, C., & Xu, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250278 · Cited by 24
“A recent clinical trial about a monoclonal antibody solanezumab failed the phase III trials for mild to moderate AD [61], but later it was found that it has benefits for a subgroup of patients with mild symptoms [62], supporting that patient subgrouping is important.”
BackgroundHao, L., Jia, J., Xing, Y., & Han, Y. (2021) · Aging & Mental Health · doi:10.1080/13607863.2021.1980860 · Cited by 24
“…by the different composition of different cohorts, which were also attributed to the controversial outcomes existing among the previous reports (Elmstahl & Widerstrom, 2014; Joo et al., 2018; Katayama et al., 2020; Knopman et al., 2018; Koch et al., 2019; Panpalli & Yilmaz, 2020; Petersen et…”
ResultGiampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 25
Kanagasingam, S., von Ruhland, C. J., Welbury, R. R., Chukkapalli, S. S., & Singhrao, S. K. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220029 · Cited by 29
Esquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 27
“A majority of patients were APOE4-positive, with nearly 60% in EXPEDI-TION and EXPEDITION 2 and 70% in EXPEDI-TION 3 [22, 23].”
BackgroundAnti-amyloid Antibody Therapies for Alzheimer’s Disease
Park, K. W. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00848-3 · Cited by 26
“As such, the clinical efficacy of solanezumab in patients with mild AD has not been established [28].”
Liu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
“A clinical phase III study found that Solanezumab did not improve the cognition of AD patients using the Alzheimer’s Disease Assessment Scale (ADAS), which can be used to evaluate the severity of dementia [94].”
MethodCerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
Rostgaard, N., Waldemar, G., Nielsen, J. E., & Simonsen, A. H. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000381828 · Cited by 24
Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease
Kurz, A., & Grimmer, T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.945907 · Cited by 23
Protein structures in Alzheimer's disease: The basis for rationale therapeutic design
Montoliu‐Gaya, L., & Villegas, S. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.10.005 · Cited by 28
Recapitulating Amyloid ß and Tau Pathology in Human Neural Cell Culture Models—Clinical Implications
Choi, S. H., Kim, Y. H., D’Avanzo, C., Aronson, J., Tanzi, R. E., Kim, D. Y., Associate, P., & Professor (2015) · touchREVIEWS in Neurology · doi:10.17925/usn.2015.11.02.102 · Cited by 29
Hara, H., Ono, F., Nakamura, S., Matsumoto, S., Jin, H., Hattori, N., & Tabira, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160514 · Cited by 24
Liu, Y., Jiang, L., & Li, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6006 · Cited by 23
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
Xie, J., Wang, H., Lin, T., & Bi, B. (2017) · BioMed Research International · doi:10.1155/2017/2986460 · Cited by 22
Antibody blood-brain barrier efflux is modulated by glycan modification
Finke, J. M., Ayres, K. R., Brisbin, R. P., Hill, H. A., Wing, E. E., & Banks, W. A. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.008 · Cited by 21
Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders
Han, C., Chaineau, M., Chen, C. X. ‐., Beitel, L. K., & Durcan, T. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00047 · Cited by 22
“…over 100 compounds tested as potential therapies were either abandoned in development or failed in clinical trials, e.g., a negative Phase III trial of the once-promising AD therapy solanezumab (Doody et al., 2014), and a halted late-stage trial on the drug verubecestat for AD (Hawkes, 2017).”
BackgroundSalloway, S., Sperling, R. A., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H. Z., Ketter, N., Wang, D., Liu, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171157 · Cited by 23
Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease?
Willbold, D., & Kutzsche, J. (2019) · Molecules · doi:10.3390/molecules24122237 · Cited by 21
Kanchi, P. K., & Dasmahapatra, A. K. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107471 · Cited by 20
Li, A., Chen, Y., Visser, A., Marks, L. A. M., & Tjakkes, G. E. (2021) · Journal of Periodontology · doi:10.1002/jper.21-0292 · Cited by 22
“Most phase III clinical trials in AD therapeutics have not been found to change the disease’s trajectory, 49–52 indicating that no well-studied pharmacotherapy is available.”
Mehrazma, B., Robinson, M. J., Opare, S. K. A., Petoyan, A., Lou, J. W., Hane, F. T., Rauk, A., & Leonenko, Z. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.07.022 · Cited by 23
“The common classes of drugs being explored that target Aβ are small nonspecific molecules (e.g., tramiprosate and flurizan) [14,15], or very large specific monoclonal antibodies (MAbs) including Bapineuzumab and Solanezumab [16,17]; to date these interventions have failed in or before Phase III clinical trials [16–20].”
BackgroundAlzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Plasma/cerebrospinal fluid biomarker findings also indicated target engagement by solanezumab and the incidence of ARIA with edema or hemorrhage was not significantly different from placebo (67, 68).”
BackgroundMolecular Therapeutics in Development to Treat Alzheimer’s Disease
Tartaglia, M. C., & Ingelsson, M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00738-6 · Cited by 25
Khalifa, K. N., Bergland, A. K., Soennesyn, H., Oppedal, K., Oesterhus, R., Dalen, I., Larsen, A. I., Fladby, T., Brooker, H. J., Wesnes, K. A., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00916 · Cited by 24
“There are no disease-modifying treatments available, and several phase III trials with anti-amyloid agents have failed (6) with some mixed but slightly more promising results with phase-III aducanumab recently reported (7, 8).”
BackgroundRoh, H. W., Kim, N., Lee, D. A., Cheong, J. Y., Seo, S. W., Choi, S. H., Kim, E., Cho, S. H., Kim, B. C., Kim, S. Y., et al. (2022) · Psychiatry Investigation · doi:10.30773/pi.2021.0335 · Cited by 28
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 24
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
“Subsequently, more than fi ve A β -targeted monoclonal antibodies have been studied in clinical trials, mainly in prodromal and early AD patients, but most of them failed to meet their primary objectives [17 – 20].”
Zhang, H., Chen, Y., Yu, M., Xi, Y., Han, G., Jin, Y., Wang, G.-J., Sun, X., Zhou, J., & Ding, Y. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304213120 · Cited by 21
“Although clinical trials of solanezumab and ponezumab were designed for blood A β clearance, these agents can only induce A β efflux from the brain through a vacuum sucking effect (36, 37).”
Self-citationDrugs and drug delivery systems targeting amyloid-β in Alzheimer's disease
Robinson, M., Lee, B., & Leonenko, Z. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.3.332 · Cited by 22
Wang, Z., Xiong, L., Wan, W., Duan, L., Bai, X., & Zu, H. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00032 · Cited by 22
“Unfortunately, all the drugs targeting Aβ through immunotherapy or secretase inhibitors have failed to improve cognitive function in AD patients (Doody et al., 2014; Salloway et al., 2014; Lovestone et al., 2015).”
BackgroundAducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease
Gamage, K. K., & Kumar, S. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0420-17.2017 · Cited by 22
Membrane Aging as the Real Culprit of Alzheimer’s Disease: Modification of a Hypothesis
Yu, Q., & Zhong, C. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0192-4 · Cited by 22
Kahle‐Wrobleski, K., Andrews, J. S., Belger, M. A., Ye, W., Gauthier, S. G., Rentz, D. M., & Galasko, D. (2017) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.2 · Cited by 21
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 22
Zhao, Y., Zhao, W., Chai, X., Sun, P., Huang, J., Guo, X., Zhang, L., Ren, D., Yi, C., Zhu, X., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.04.025 · Cited by 34
Patricio-Martínez, A., Patricio, F., Macuil-Chapuli, E., Martínez-Juárez, E. Á., Flores-Díaz, S., Cedillo-Ramirez, M. L., & Limón, I. D. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1598011 · Cited by 28
Lundkvist, J., Halldin, M. M., Sandin, J., Nordvall, G., Forsell, P. K. A. L., Svensson, S., Jansson, L., Johansson, G., Winblad, B. G., & Ekstrand, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00102 · Cited by 27
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Wang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 23
“where yijk , I, μ0, and Δj1 have the same meaning as those in (2); θ is defined in the same way as in (1) with the same assumptions; u0i , u1i are the random effects for the intercept and the change from baseline and are assumed to follow the same bivariate normal distribution for both groups: ( u0i u1i ) ∼ N ( 0, [ σ…”
BackgroundMethodAging phenotype in AD brain organoids: Track to success and challenges
Hossain, M. K., Kim, H., & Chae, H. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102256 · Cited by 27
“This limitation has led to the disappointment of potential AD drugs that initially showed promising therapeutic effects in early animal studies but failed in phase III clinical trials(Doody et al., 2014; Salloway et al., 2014).”
BackgroundChhabra, A., Solanki, S., Saravanabawan, P., Venkiteswaran, A., Nimmathota, N., & Modi, N. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2416947 · Cited by 26
Turano, E., Busetto, G., Marconi, S., Guzzo, F., Farinazzo, A., Commisso, M., Bistaffa, E., Angiari, S., Musumeci, S., Sotgiu, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.033 · Cited by 21
How Clinical Development Can, and Should, Inform Translational Science
Barker‐Haliski, M. L., Friedman, D. J., White, H. S., & French, J. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.029 · Cited by 22
Targeting tau protein in Alzheimer's disease
Rafii, M. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32107-9 · Cited by 23
Fu, L., Li, Y., Hu, Y., Zheng, Y., Yu, B., Zhang, H., Wu, J., Wu, H., Yu, X., & Kong, W. (2017) · Scientific Reports · doi:10.1038/srep41041 · Cited by 22
Shen, J. (2014) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000167 · Cited by 20
McGraw, C. M., Ward, C. S., & Samaco, R. C. (2017) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31570 · Cited by 24
“Indeed, two antibody-based therapies, solanuzumab and bapineuzumab, did not meet their primary study endpoints of cognitive improvement in clinical trials (Doody et al., 2014; Salloway et al., 2014; The Lancet Neurology, 2017).”
BackgroundRole of alpha1-adrenergic receptor antibodies in Alzheimer lsquo s disease
Bimmler, M. (2018) · Frontiers in bioscience · doi:10.2741/4691 · Cited by 20
Ishida, T., Tokuda, K., Hisaka, A., Honma, M., Kijima, S., Takatoku, H., Iwatsubo, T., Moritoyo, T., Suzuki, H., & Initiative, T. A. D. N. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1166 · Cited by 22
“In AD, cognitive function tests have mainly been used to include subjects with dementia in the clinical trial of an anti–amyloid- β antibody.(6) (b) The proposed criterion, in which subjects with disease times falling within a specific interval are recruited (“criterion in time”).”
BackgroundMethodSelf-citationAMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 22
Suhara, T., Chaki, S., Kimura, H., Furusawa, M., Matsumoto, M., Ogura, H., Negishi, T., Saijo, T., Higuchi, M., Omura, T., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw111 · Cited by 21
Setbacks in Alzheimer research demand new strategies, not surrender
Jobke, B., McBride, T. C., Nevin, L. M., Peiperl, L., Ross, A. J., Stone, C., Turner, R. C., & Editors, A. T. P. M. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002518 · Cited by 20
Holdridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
“12 In this subpopulation,aconsistenteffectofsolanezumabwasobservedacrossmultiple clinical outcomes in the individual studies as well as analyses of pooled data from both studies.”
Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 24
“…a humanized monoclonal antibody targeting the mid-domain of the A β peptide, was subjected to two phase III trials, EXPEDITION 1 (NCT00905372) and EXPEDITION 2 (NCT00904683), which ultimately failed to demonstrate efficacy in slowing cognitive decline in mild-to-moderate AD patients [137].”
Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease
Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 22
“First-generation mAbs, such as Solanezumab [114], bapineuzumab [29,115], crenezumab [116], aimed at A β monomers or generic epitopes did not significantly improve outcomes in Phase III trials despite lowering some biomarkers.”
Kanchi, P. K., & Dasmahapatra, A. K. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04968-x · Cited by 21
Aquino, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694329 · Cited by 24
Zhu, H., Mehta, M., Huang, S. M., & Wang, Y. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2536 · Cited by 20
“indicated that “SUVR did not significantly change in the solanezumab group or in placebo group” in either study.(6) Percentage change from baseline in Centiloid was used in panel b to account for different baseline levels in patients enrolled in trials for donanemab”
MethodRecent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer’s Disease
Su, M., Nizamutdinov, D., Liu, H., & Huang, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119272 · Cited by 28
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
“…caused a large increase in total CSF Aβ 1–42 levels in subjects with dominantly inherited AD (+1341 pg/mL) [49] and in sporadic AD patients (up to +727 pg/mL) [38] related to the bound fraction of Aβ 1–42 while the free Aβ 1–42 fraction could be unchanged or reduced due to antibody binding.”
BackgroundInfluentialFernández-Fúnez, P., Zhang, Y., Sanchez-Garcia, J., de Mena, L., Khare, S., Golde, T. E., Levites, Y., & Rincón-Limas, D. E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv321 · Cited by 21
Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
Apter, J. T., Shastri, K., & Pizano, K. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0141-x · Cited by 20
Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
Paquet, C., Magnin, É., Wallon, D., Troussière, A., Dumurgier, J., Jager, A., Bellivier, F., Bouaziz-Amar, É., Blanc, F., Beaufils, É., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0192-z · Cited by 19
Kim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 22
Kim, H. Y., Kim, H. V., Lee, D. K., Yang, S., & Kim, Y. S. (2016) · Scientific Reports · doi:10.1038/srep34165 · Cited by 21
Wu, P.-C., Fann, M., Tran, T. T., Chen, S.-C., Devina, T., Cheng, I. H.-J., Lien, C., Kao, L., Wang, S., Fuh, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55614-9 · Cited by 18
Wang, X., Xia, W., Li, K., Zhang, Y., Ge, W., & Ma, C. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.02.022 · Cited by 20
Recent Advances in Antibody Therapy for Alzheimer’s Disease: Focus on Bispecific Antibodies
Yang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136271 · Cited by 21
Kirson, N. Y., Andrews, J. S., Desai, U. S., King, S. B., Schonfeld, S. A., Birnbaum, H. G., BALL, D. E., & Kahle‐Wrobleski, K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170078 · Cited by 22
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 21
Piccirella, S., Neste, L. V., Fowler, C., Masters, C. L., Fripp, J., Doecke, J. D., Xiong, C., Uberti, D. L., & Kinnon, P. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.52 · Cited by 17
“For more than 15 years, different disease-modifying treatments (DMTs) have been investigated, yet none of them were found to be clinically effective, (4-6) except for aducanumab, which was recently approved by the Food and Drug Administration (FDA) for treatment of AD dementia at the MCI stage (7, 8).”
BackgroundDisease progression model using the integrated Alzheimer's Disease Rating Scale
Gueorguieva, I., Chua, L., Willis, B. A., Sims, J. R., & Wessels, A. M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12876 · Cited by 19
Mohanty, M., & Kumar, P. (2022) · Geriatrics · doi:10.3390/geriatrics8010004 · Cited by 23
“treatments in dementia or mild cognitive impairment (MCI) stages failed [10,11].”
BackgroundLin, Q., Shahid, S. S., Hone‐Blanchet, A., Huang, S., Wu, J., Bisht, A. S., Loring, D. W., Goldstein, F. C., Levey, A. I., Crosson, B., et al. (2023) · Human Brain Mapping · doi:10.1002/hbm.26263 · Cited by 22
“…tangles of hyperphosphorylated tau proteins in the brain are two hallmarks of AD (Jack et al., 2018; Selkoe, 1991), recent clinical trials (Doody et al., 2014; Salloway et al., 2014) targeting the reduction of Aβ burden have failed to show positive effects on cognitive outcomes despite…”
BackgroundDayarathna, T. K., Roseborough, A. D., Gomes, J., Khazaee, R., Silveira, C. R. A., Borron, K., Yu, S., Coleman, K. K. L., Jesso, S., Finger, E. C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14087 · Cited by 19
“8 With-out reliable biomarkers of early AD, clinical trials are at risk of inaccurate and delayed enrollment of patients.”
Norton, M. C., Clark, C. J., Tschanz, J. T., Hartin, P. J., Fauth, E. B., Gast, J. A., Dorsch, T. E., Wengreen, H. J., Nugent, C., Robinson, W. D., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.05.001 · Cited by 25
Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases
Wootla, B., Watzlawik, J. O., Warrington, A. E., Wittenberg, N. J., Đenić, A., Xu, X., Jordan, L. R., Papke, L. M., Zoecklein, L. J., Pierce, M. L., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2188 · Cited by 21
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 21
Organofluorine Compounds in Neurological Disorders
Reddy, V. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53748-5.00008-3 · Cited by 21
Petrushina, I., Davtyan, H., Hovakimyan, A., Davtyan, A., Passos, G. F., Cribbs, D. H., Ghochikyan, A., & Agadjanyan, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.002 · Cited by 20
Martín‐Peña, A., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-11594-2 · Cited by 19
Geerts, H., & Spiros, Ä. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12082 · Cited by 21
Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia
Hannestad, J. O., Koborsi, K., Klutzaritz, V., Chao, W., Ray, R., Páez, A., Jackson, S., Lohr, S., Cummings, J. L., Kay, G. G., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12115 · Cited by 16
“Patients withmoderate adverse events 3 (13) 7 (30)”
BackgroundPseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies
Robinson, M. J., Lou, J. W., Mehrazma, B., Rauk, A., Beazely, M. A., & Leonenko, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031051 · Cited by 17
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.